Plasma cholesterol lowering in an AngII-infused atherosclerotic mouse model with moderate hypercholesterolemia

ARÁNZAZU ROSSIGNOLI1, EMINA VORKAPIC2, ANDERS WANHAINEN3, TOSTE LÄNNE4, JOSEFIN SKOGBERG1, ERIKA FOLESTAD1 and DICK WÅGSÄTER2

1Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm; 2Division of Drug Research, Department of Medical and Health Sciences, Linköping University, 58183 Linköping; 3Department of Surgical Sciences, Section of Vascular Surgery, Uppsala University, 75185 Uppsala; 4Division of Cardiovascular Medicine, Department of Medical and Health Sciences, Linköping University, 58183 Linköping, Sweden

Received September 15, 2017; Accepted February 22, 2018

DOI: 10.3892/ijmm.2018.3619

Abstract. Atherosclerosis is the main underlying causes of cardiovascular disease. There is a well-established association between high blood cholesterol levels and the extent of atherosclerosis. Furthermore, atherosclerosis has been proposed to augment abdominal aortic aneurysm (AAA) formation. As patients with AAA often have parallel atherosclerotic disease and are therefore often on cholesterol-lowering therapy, it is not possible to fully address the independent effects of plasma cholesterol lowering (PCL) treatment on AAA. The present study investigated the effect of angiotensin II (AngII)-infusion in modestly hypercholesterolemic Ldlr-/- Apob100/100 Mttpflox/flox Mx1-Cre mice with or without PCL treatment on a morphological and molecular level, in terms of atherosclerosis and AAA development. AngII infusion in the study mice resulted in an increased atherosclerotic lesion area and increased infiltration of inflammatory leukocytes, which was not observed in mice with PCL induced prior to AngII infusion. This suggested that AngII infusion in this mouse model induced atherosclerosis development, and that plasma cholesterol levels represent a controlling factor. Furthermore, AngII infusion in Ldlr-/- Apob100/100 Mttpflox/flox Mx1-Cre mice caused a modest aneurysmal phenotype, and no differences in AAA development were observed between the different study groups. However, the fact that modest hypercholesterolemic mice did not develop AAA in a classical atherosclerotic model indicated that plasma cholesterol levels are important for disease development.

Introduction

Abdominal aortic aneurysm (AAA) is a relatively common and potentially lethal disease. The most important risk factors associated with AAA include smoking, being male, age and family history (1-3). Coexisting atherosclerosis is a common feature in patients with AAA. Although AAA and atherosclerosis share certain common risk factors (1,4), there are important histopathological and epidemiological differences that suggest they should be regarded as separate disease entities.

AAA is a relatively complex disease, and the mechanisms underlying the development and progression of the disorder remain to be completely understood. However, the main pathological hallmarks of established AAs are chronic inflammation, vascular smooth muscle cell (vSMC) apoptosis, and extracellular matrix degradation in the media layer (2,4).

The mechanisms driving atherosclerotic progression are characterized by a pathological build-up of plaque within the intimal layer, where endothelial dysfunction, proliferation of smooth muscle cells, macrophage infiltration and the accumulation of lipids serve central functions (5).

The involvement of atherosclerosis in aneurysm pathology is unclear. A common feature of potential interest is that AAA and atherosclerosis result in a clear inflammatory response (4). Hypercholesterolemia is associated with the development of atherosclerosis, but its association with AAA remains indistinct (4,6). Studies using rodent models have suggested that treatment with plasma cholesterol lowering (PCL) statins attenuate aneurysmal growth in experimentally-induced AAs (7,8). However, results in humans are more conflicting. One previous study demonstrated that statins reduce the expression of selected inflammatory mediators within the aortic vessel wall, independent of their lipid lowering effects (9). Earlier clinical association studies indicated a potential growth inhibitory effect of statins on AAA, but this was not confirmed in larger, more recent studies (10-12).

The aim of the present study was to further investigate the association between AAA and atherosclerosis and, more specifically, how PCL treatment affects the development of AAA in the Ldlr-/- Apob100/100 Mttpflox/flox Mx1-Cre mouse model. This is
an atherosclerotic mouse model that has a plasma cholesterol profile similar to that of human hypercholesterolemia, with plasma cholesterol levels of 300–400 mg/dl on a regular chow diet, and develops atherosclerosis along the whole aortic tree. Furthermore, Ldlr<sup>−/−</sup>Apop<sup>100/100</sup>Mttp<sup>flox/flox</sup>Mx1-Cre mice have a genetic switch that allows lowering of plasma cholesterol levels at any desirable time point (13,14). Previous studies in Ldlr<sup>−/−</sup>Apop<sup>100/100</sup>Mttp<sup>flox/flox</sup>Mx1-Cre mice revealed that PCL treatment resulted in complete regression in mice with early atherosclerotic lesions, but was incomplete in mice with mature and advanced atherosclerotic lesions (13). Infusion of Angiotensin II (AngII) into mice is a well-established method to induce AAA. Aneurysm development has been reported to be markedly lower in AngII-treated wild-type C57BL/6 (non-hyperlipidemic) mice compared with hyperlipidemic mice, including Ldlr<sup>−/−</sup> or apoE<sup>−/−</sup> mice (15). This suggests that hyperlipidemia may be of importance for AngII-induced AAA. Ldlr<sup>−/−</sup>Apop<sup>100/100</sup>Mttp<sup>flox/flox</sup>Mx1-Cre mice have not previously been used in studies on AAA formation. Therefore, AAA was induced in Ldlr<sup>−/−</sup>Apop<sup>100/100</sup>Mttp<sup>flox/flox</sup>Mx1-Cre (14,16) by AngII-infusion to investigate its morphological and molecular effects on atherosclerosis and AAA establishment, as well as the effect of PCL therapy preceding AngII-infusion.

Materials and methods

Ethics statement. The present study was performed in accordance with Swedish legislation of animal welfare. The protocol for the present study was approved by the Stockholm North Ethical Committee on Animal Research (ethical permit no. N223/14). All animals used in the present study were monitored daily by the animal facility staff. Whenever illness was observed or suspected, animals were assessed according to the Karolinska Institutet extended assessment checklist for small rodents and rabbits, and euthanized if a total score of 0.3 was reached (17,18). Animals were kept in a specific pathogen-free animal facility with a controlled temperature of 22°C and 12/12 h day-night cycle lightning. They were communally housed in standard cages with enrichment in the form of nesting material, and had ad libitum access to food and water.

Animals. Male Ldlr<sup>−/−</sup>Apop<sup>100/100</sup>Mttp<sup>flox/flox</sup>Mx1-Cre (1D 004192-Mtpptm2Sgy Ldlrtm1Her Apobtm2Sgy Tg(Mx1-cire)Cgn/J) were obtained from the Jackson Laboratory for breeding (Bar Harbor, ME, USA; www.jax.org). All experiments were performed in mice bred in Scheele Animal Facility at Karolinska Institute. Mice were kept in standard cages with enrichment in form of nesting material and had free access to food/water. A total number of 75 mice were divided in three different groups and used in the study. Mice used had a weight of 20-25 g at the start of experiment. PCL was performed in 19-week-old mice by intraperitoneal injection (ip) of 200 µl polyinosinic-polycytidylic acid (pl-pC; 1 µg/µl, Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) every other day for a week to induce Cre expression and thereby Mttp recombination (Mttp<sup>flox</sup>Δ). Littermate controls received PBS (Mttp<sup>flox/flox</sup>). To induce aneurysm formation, micro-osmotic pumps (model 1004; Alzet; Durect Corporation, Cupertino, CA, USA) containing AngII (1,000 ng kg-1 min-1; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) or saline (PBS; 0.9% NaCl) were implanted subcutaneously into the back of the mice one week after PCL treatment under isoflurane-induced anesthesia (2%; Baxter Healthcare Corporation; Deerfield, IL, USA). One dose of buprenorphine (Temgesic; 10 µg/ml) was given subcutaneously as an analgesic prior to surgery.

To determine whether Ldlr<sup>−/−</sup>Apop<sup>100/100</sup>Mttp<sup>flox/flox</sup>Mx1-Cre mice developed AAA following AngII-infusion, several different starting points (including the age of mice) were investigated, as well as the duration of the AngII-infusion. In brief, AngII-containing pumps were implanted at 8 or 20 weeks of age for a period of 4 or 8 weeks. The group with the pump implanted at 20 weeks of age for 8 weeks was selected for further PCL experiments based on the degree of vascular remodeling following AngII-infusion.

Animals were monitored for any sign of pain. Blood from the tail vein or heart was collected in heparin-coated tubes prior to and following PCL treatment, and at the point of sacrifice. The osmotic pump was implanted at 20 weeks of age for 8 weeks (4+4). The study mice were sub-divided in 3 groups (n=9-12/group) as follows: Group 1, mice administered with PBS ip one week prior to implantation of pumps containing saline (Control, Ctrl); Group 2, mice administered with PBS ip one week prior to implantation of pumps containing AngII (AngII); and Group 3, mice administered with pl-pC one week prior to implantation of pumps containing AngII (AngII+PCL). Following the AngII-infusion period, mice were sacrificed by placing them in a chamber connected to a CO₂ gas bottle and the lowest possible flow rate of ~1 L/min was used. The container was slowly filled with CO₂ gas until asphyxiation of the mice. Mice were confirmed dead by assessing lack of heart beats for several minutes, after which the chest cavity was opened and thereafter blood was collected from cardiac puncture and then the right ear of the heart was cut. Aortas were collected.

Plasma analysis. Total plasma cholesterol and triglycerides were measured with the following colorimetric assays: Infinity Triglyceride (Reference no. TR22421; Thermo Fisher Scientific, Inc.) and Infinity Cholesterol (Reference no. TR13421; Thermo Fisher Scientific, Inc.), using a POLARstar Omega plate reader (BMG Labtech GmbH, Ortenberg, Germany) according to the manufacturer's protocol. Plasma glucose levels were measured in non-starved mice using plasma taken from either the tail vein or the heart, with a Bayer Contour XT glucose meter and glucose test strips (Bayer AG, Leverkusen, Germany). The measured glucose levels were converted from nmol/l to mg/dl with the conversion factor 1 mmol/l=18.018 mg/dl.

Immunohistological staining and analysis of the suprarenal aorta. Some suprarenal aorta samples were collected in 4% zinc formaldehyde fixative solution (Histolab Products AB, Spånga, Sweden) in room temperature for 24 h and then changed into PBS until embedded in paraffin, sectioned (5 µm) and rehydrated using a descending alcohol series (X-tra Solv, 99, 95 and 70% ethanol). The rest of the aortas were collected in 4% paraformaldehyde (PFA; Sigma-Aldrich; Merck KGaA). PFA aortas were cleaned, cut into longitudinal sections, pinned out on black wax plates and stained with Sudan IV (5 g/l Sigma-Aldrich; Merck KGaA) for 6 min at room
temperature. Images of sections were captured using a light microscope Nikon SMZ1000 microscope (Nikon Corporation, Tokyo, Japan) and quantified using an AxioGraphic station (Carl Zeiss AG, Oberkochen, Germany). Lesion area was calculated as the percentage of the total aortic area (the whole aortic tree from the aortic root until directly before the point where the iliac branches start). Antigen retrieval was performed using Diva Decloaker, 20X (Biocare Medical, LLC, Paheco, CA, USA) according to the manufacturer's protocol, endogenous peroxidase activity was blocked with 3% hydrogen peroxide, and sections were subsequently incubated in 5% goat serum solution (Vector Laboratories, Burlingame, CA, USA) 1 h in room temperature. Then, sections were incubated with primary antibodies against mouse cluster of differentiation (CD)68 (1:500; cat. no. MCA1957; AbD Serotec; Bio-Rad Laboratories, Inc., Hercules, CA, USA) and transglelin (SM22α; 1:4,000; cat. no. ab14106; Abcam, Cambridge, UK) overnight at 4°C. Sections were washed in PBS-Tween (0.05%) 2x10 min. Thereafter, sections were incubated with secondary biotinylated rabbit anti-rat immunoglobulin G (IgG) (1:500; cat. no. BA-4001; Vector Laboratories, Ltd., Peterborough, UK) or goat anti-rabbit IgG antibodies (1:500; cat. no. BA-1000; Vector Laboratories, Ltd., Peterborough, UK) (SM22α) 1 h in room temperature. Avidin-biotin complexes (from the VECTASTAIN Elite ABC HRP kit; cat. no. PK-6100; Vector Laboratories, Ltd.) were added according to the manufacturer's protocol, and this was followed by staining with a DAB Peroxidase (HRP) Substrate kit (with nickel; cat. no. SK-4100; Vector Laboratories, Ltd.) according to the manufacturer's protocol. Sections were counterstained with QS hematoxylin (Vector Laboratories, Ltd.), visualized using a light microscope (AxioObserver, Carl Zeiss AG) and quantified with an AxioGraphic station (Carl Zeiss AG). For collagen staining, sections were incubated in Bouin's solution (Sigma-Aldrich; Merck KGaA) overnight, counterstained with Weigert's hematoxylin (Histolab Products AB), stained with a Masson Trichrome kit (Sigma-Aldrich; Merck KGaA) at room temperature and washed in 1% acetic acid according to the manufacturer's protocol. Mounted slides were visualized using an AxioCam ICC 1 light microscope (Carl Zeiss AG). Quantification and scoring of collagen and elastin was performed in whole aortic section and 3 whole sections per mouse were averaged. Two different blinded and experienced scientists performed the scoring of sections, in case of disagreement their results were averaged. The images were captured at x10 and x40 magnification. A scoring from 1 to 4 was assigned to assess the variation in the degree of elastin degradation as follows: 1, intact elastin; 2, a low degree of degradation; 3, intermediate degradation; and 4, a high degree of degradation. Substantial vascular remodelling was defined as a >50% increase in medial thickness compared with baseline values, which were defined as the average medial thickness from the control group mice. AAA was defined as a >50% increase in the diameter of the aorta compared with baseline values, which were defined as the average of the aortic diameter from the control group mice.

**Gene expression analysis.** Suprarenal aortic samples were dissected, cleaned and stored in RNAlater (Ambion; Thermo Fisher Scientific, Inc.) at 80°C. RNA was extracted using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), homogenized with a FastPrep instrument (MP Biomedicals, LLC, Santa Ana, CA, USA) and purified with an RNeasy Mini kit with a DNase1 treatment step (Qiagen, Inc., Valencia, CA, USA). RNA quantity was determined using a Nanodrop spectrometer (Thermo Fisher Scientific, Inc.). RNA was reversed transcribed using Superscript III First-strand Synthesis SuperMix (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol, and cDNA was amplified using quantitative polymerase chain reaction (qPCR) analysis using TaqMan Fast Universal PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) in a 7300 Real-Time PCR System according to the manufacturer's protocol (Applied Biosystems; Thermo Fisher Scientific, Inc.). TaqMan Assay kits (Applied Biosystems; Thermo Fisher Scientific, Inc.) containing primers and probes were used for the following genes: Cd68 (Mm00839636_g1), filamin A (Flna; Mm01187533_m1), matrix metalloproteinase (Mmp)12 (Mm00505554_m1), Mmp9 (Mm00600163_m1), Cd3 (Mm00599683_m1), collagen type I α1 chain (Coll1; Mm00801666_m1) and Mast cell protease 9 (Mcpt9; Mm00775987_g1), and gene expression values were normalized to the house-keeping gene TATA-box binding protein (Mm00446973_m1). Samples were analyzed in duplicate using the standard curve method following the applied biosystems protocol (19).

**En face analysis of aortas.** Aortic arches collected in 4% PFA were dissected, cleaned, cut into longitudinal sections and pinned out on black wax plates as previously described (20) stained with Sudan IV (Sigma-Aldrich; Merck KGaA), photographed with a light Nikon SMZ1000 microscope (Nikon Corporation) and quantified using an AxioGraphic station (Carl Zeiss AG). Lesion area was calculated as the percentage of the total aortic arch surface.

**Blood pressure measurements.** Blood pressure was recorded in isoflurane-anesthetised mice at the end of the experiment, one day prior to sacrifice, with a CODA Non-Invasive Blood Pressure System (Kent Scientific Corporation, Torrington, CT, USA) using an Occlusion tail cuff and a Volume Pressure Recorder sensor tail cuff, as previously described (21). Mice were anaesthetised for 15 min under 1.5% isoflurane, and were maintained at 35°C during the procedure. A total of 10 measurements were recorded following an acclimation period of 10 cycles.

**Statistical analysis.** The data were analyzed using GraphPad Prism software (version 7.0; GraphPad Software, Inc., La Jolla, CA, USA). Results are presented as the mean ± standard error of the mean. Data analysis was accomplished using one-way analysis of variance with Tukey's post hoc analysis, or Kruskal-Wallis tests followed by Dunn's multiple comparisons test. P<0.05 was considered to indicate a statistically significant difference.
Results

Atherosclerosis development in AngII-infused Ldlr<sup>−/−</sup>Apo<sub>b100/100</sub>Mttp<sup>fox/fox</sup>Mx1-Cre mice. Baseline plasma profiles (cholesterol, triglycerides and glucose) were similar for the three different study groups (Ctrl, AngII and AngII+PCL; Table 1). As expected, the plasma levels of cholesterol (+32%), triglycerides (+63%) and glucose (+38%) were increased in the control group compared with baseline values. Infusion of AngII for eight weeks increased the plasma cholesterol content (+30%) and the glucose (+30%) levels in a similar manner to the control group. However, infusion of AngII increased the plasma triglyceride content by +100% as compared with baseline values; a more pronounced increase than that in the control group. In PCL-treated animals, AngII infusion resulted in significantly decreased plasma cholesterol (-80%) levels, unchanged triglyceride content and a minor increase in the amount of glucose (+10%) as compared with the baseline levels (Table 1). Control and AngII-infused mice had markedly increased plasma cholesterol, triglyceride and glucose levels when compared with starting values, which was not observed in animals with PCL treatment prior to AngII infusion. These results demonstrated that typical plasma parameters known to be regulated in atherosclerosis increased following AngII infusion in the mice without PCL.

Figure 1. Atherosclerotic lesion characterization of AngII-infused Ldlr<sup>−/−</sup>Apo<sub>b100/100</sub>Mttp<sup>fox/fox</sup>Mx1-Cre mice. (A) Percentage of lesion area, quantified by Sudan IV staining of the total aorta (left). Representative images of the total aortic tree magnified at x0.8 at the dissection microscope, for Ctrl (n=5), AngII (n=5) and AngII+PCL (n=5) mice. (B) Percentage of SM22α stained area of total aortic root cross-sections (left) and representative images (right) for the quantified immunohistochemical staining (Ctrl, AngII, AngII+PCL; n=6-11). (C) Percentage of CD68 stained area of total aortic root cross-sections (left) and representative images (right) for the quantified immunohistochemical staining (Ctrl, AngII, AngII+PCL; n=6-11). (D) Systolic blood pressure (Ctrl, AngII, AngII+PCL; n=3). Statistical significance was analyzed by one-way analysis of variance with Tukey’s post hoc test, and data are presented as the mean ± standard error of the mean. Scale bars represent 50 µm. *P<0.05 and ***P<0.001, with comparisons indicated by lines. AngII, angiotensin II; PCL, plasma cholesterol lowering; Ctrl, control.
consistent with the plasma measurements, PCL pretreatment was demonstrated to reduce the development of atherosclerosis compared with non-treated, AngII-induced animals, which developed a similar atherosclerotic lesion area to the control mice (Fig. 1A). Immunohistological staining revealed that the smooth muscle cell marker SM22α remained largely unaffected in the different study groups (Fig. 1B). CD68 staining for cellular infiltration of inflammatory leukocytes was significantly increased in non-PCL-treated AngII-infused mice compared with mice with PCL pretreatment (Fig. 1C). Furthermore, measuring systemic systolic blood pressure revealed that AngII-infused animals without PCL pretreatment exhibited significantly higher blood pressure than mice with PCL (Fig. 1D).

Consistent with the plasma measurements, PCL pretreatment was demonstrated to reduce the development of atherosclerosis compared with non-treated, AngII-induced animals, which developed a similar atherosclerotic lesion area to the control mice (Fig. 1A). Immunohistological staining revealed that the smooth muscle cell marker SM22α remained largely unaffected in the different study groups (Fig. 1B). CD68 staining for cellular infiltration of inflammatory leukocytes was significantly increased in non-PCL-treated AngII-infused mice compared with mice with PCL pretreatment (Fig. 1C). Furthermore, measuring systemic systolic blood pressure revealed that AngII-infused animals without PCL pretreatment exhibited significantly higher blood pressure than mice with PCL (Fig. 1D).

Taken together, these results indicated that Ldlr<sup>−/−</sup> Apob<sup>100/100</sup> Mttp<sup>flx/flx</sup> Mx1-Cre mice infused with AngII developed distinguishable atherosclerosis, as compared with control animals or mice with PCL prior to AngII-infusion.

### AAA development in AngII-infused Ldlr<sup>−/−</sup> Apob<sup>100/100</sup> Mttp<sup>flx/flx</sup> Mx1-Cre mice.

AAA development was monitored in the Ldlr<sup>−/−</sup> Apob<sup>100/100</sup> Mttp<sup>flx/flx</sup> Mx1-Cre mice (Fig. 2). After 8 weeks of AngII-infusion, the increase in aortic diameter was modest and did not differ significantly between the three

#### Table I. Plasma measurements of the difference mouse study groups.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>CHL start (mg/dl)</th>
<th>CHL sacrifice (mg/dl)</th>
<th>TG start (mg/dl)</th>
<th>TG sacrifice (mg/dl)</th>
<th>Glucose start (mg/dl)</th>
<th>Glucose sacrifice (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>163±10.1</td>
<td>216±14.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>36.6±5.1</td>
<td>59.7±3.8&lt;sup&gt;b&lt;/sup&gt;</td>
<td>209±8.3</td>
<td>288±9.1&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>AngII</td>
<td>173±8.3</td>
<td>225±14.3&lt;sup&gt;b&lt;/sup&gt;</td>
<td>40.5±3.4</td>
<td>82.2±6.3&lt;sup&gt;d&lt;/sup&gt;</td>
<td>207±7.7</td>
<td>268±12.1&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>AngII+PCL</td>
<td>178±11.7</td>
<td>36.7±4.1&lt;sup&gt;c,d&lt;/sup&gt;</td>
<td>34.9±2.8</td>
<td>36.2±2.4&lt;sup&gt;c,d&lt;/sup&gt;</td>
<td>201±5.8</td>
<td>224±12.2&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>P<0.05 and <sup>b</sup>P<0.001 vs. starting value. <sup>c</sup>P<0.001 vs. control group. <sup>d</sup>P<0.001 vs. AngII group. Data are presented as the mean ± standard error of the mean. There were no significant differences between the groups at the beginning of the present study. PCL, plasma cholesterol lowering; AngII, angiotensin II; CHL, cholesterol; TG, triglycerides.
groups (Fig. 2A, B and F). A total of 17% of PCL-treated mice developed an aneurysmal phenotype, compared with 23% of non-treated AngII-induced mice (Fig. 2A-C). Medial thickness was slightly increased in the two AngII-infused mice groups compared with saline-infused control animals (Fig. 2A and D). Mice with and without PCL prior to AngII-infusion exhibited vascular remodeling in 50 and 54% of cases, respectively (Fig. 2A and E). Overall aneurysmal formation was low in the Ldlr<sup>−/−</sup> Apob<sup>100/100</sup> Mttp<sup>fox/fox</sup> Mx1-Cre mouse model, and in order to obtain a larger study group, all time points used in the pilot study were analyzed together with the 8 week study (Fig. 3). Data from the larger cohort revealed similar results.

Histological staining and scoring of collagen in cross sections of suprarenal aortas demonstrated a slight, non-significant increase of collagen production in the AngII-infused groups compared with the control animals (Fig. 2A and G). Further histological staining and scoring of elastin revealed small, but significant differences in elastin degradation in non-PCL-treated AngII-infused mice, while no significant differences were observed in PCL-treated mice prior to infusion of AngII, compared with control aortas (Fig. 2A and H).

To summarize, AngII-infusion in Ldlr<sup>−/−</sup> Apob<sup>100/100</sup> Mttp<sup>fox/fox</sup> Mx1-Cre mice, a mouse model with moderately increased cholesterol levels, resulted in a low incidence of AAA that was unaffected by PCL treatment.

**Gene expression analysis in AngII-infused Ldlr<sup>−/−</sup> Apob<sup>100/100</sup> Mttp<sup>fox/fox</sup> Mx1-Cre mice.** Gene expression levels of the macrophage marker C<sub>d68</sub> were markedly elevated in the non-treated AngII-infused group as compared with control and PCL-treated animals (Fig. 4A), indicating loss of vSMC, since filamin A primarily binds to actin. Expression of Mmp12 is often elevated in AAA as a result of macrophage infiltration and collagen production. Expression of Cd3 was also elevated in the non-treated AngII-infused group, while expression of Cd11b, encoding the non-contraceptive cytoskeletal protein filamin A, was decreased in non-pre-treated, AngII-infused mice as compared with control and PCL-treated animals (Fig. 4B), indicating loss of vSMC, since filamin A primarily binds to actin. Expression of Mmp12 is often elevated in AAA as a result of macrophage infiltration and collagen production.
phage infiltration (22). Mmp12 upregulation was observed in non-pretreated AngII-infused animals, but not in animals with PCL treatment prior to infusion of AngII, compared with the control (Fig. 4C). Other key AAA genes investigated, including Cd3, Colla1 and Mep19, were unaltered or exhibited changes that were not significant (Fig. 4D-F). In summary, the few alterations in gene expression and the large standard deviations in the different groups are potentially reflected by the low incidence of aneurysms. However, expression of several of the genes examined were altered in the AngII-infused group in a manner that was not observed in PCL-treated mice, indicating that plasma cholesterol levels affect disease development. Furthermore, consistent with data observed from immunohistochemical staining, Cd68 was upregulated in AngII-infused mice, but this was not observed in PCL-treated mice.

**Discussion**

In the present study, the morphological and molecular effects of PCL therapy on atherosclerosis and aneurysmal formation were evaluated in an atherosclerotic AAA mouse model. The Ldlr<sup>-/-</sup> Apob<sup>100/100</sup> Mttp<sup>flox/flox</sup> Mx1-Cre mouse model is an atherosclerotic model with a moderate increase in plasma cholesterol levels, similar to those observed in human hypercholesterolemia. This mouse model has not previously been used to examine the effects of AngII-infusion on atherosclerotic development or aneurysmal formation.

The main finding of the present study was that AngII-infusion increased plasma cholesterol and triglyceride levels, as well as atherosclerotic development. Notably, AngII-induced atherosclerosis was prevented by PCL treatment prior to infusion of AngII, which is in agreement with previous studies on the hyperlipidemic apo<sub>e</sub><sup>-</sup> mouse model (23,24). This suggests that the renin-AngII system is mechanistically involved in the pathogenesis of atherosclerosis. In addition, the present study also demonstrated that the amount of plasma cholesterol is important for atherosclerosis progression following AngII-infusion, since PCL averts the progression of atherosclerosis development. Our group previously demonstrated that PCL slows and prevents the progression of atherosclerosis regardless of lesion stage, and may lead to complete regression if PCL is induced in mice with early lesions (13). Furthermore, an increase in the infiltration of inflammatory leukocytes and systemic blood pressure was observed in AngII-infused animals, and this was also reversed by PCL. AngII is known to be involved in the regulation of blood pressure and is a potent hypertensive agent. Certain previous publications support these results (25), while others have been unable to detect any increase in blood pressure following AngII-infusion (24).

Despite its distinct effect in atherosclerosis development, as well as its impact on the expression of genes known to be involved in AAA development, the relatively low incidence of AAA in the AngII-treated Ldlr<sup>-/-</sup> Apob<sup>100/100</sup> Mttp<sup>flox/flox</sup> Mx1-Cre mice is an important limitation of the model, where PCL pretreatment had no significant effect on aneurysm formation. In other common mouse models used to study AAA, including apo<sub>e</sub><sup>-</sup> mice and Ldlr<sup>-/-</sup> mice on a high-fat diet, the occurrence of AAA formation following AngII infusion ranged from 70-80%, compared with only 20-30% observed in our model (26,27). This relatively low AAA incidence makes it difficult to determine the significance of the differences observed in the limited number of mice. However, including experiments from a pilot study and almost doubling the number of mice elicited similar results.

One explanation for the low rate of aneurysmal formation may be that the mice used in the present study were modestly hypercholesterolemic (200 mg/dl) compared with other models commonly used to study AAA, where plasma cholesterol levels reach 1,500 mg/dl (28). In a parallel study using the same batch of AngII in apo<sub>e</sub><sup>-</sup> mice, AAA occurred in 75% of the mice (data not shown). Liu et al demonstrated that hypercholesterolemia increased the development of AngII-induced AAA in mice (28), indicating that higher cholesterol levels are required for AAA formation. Furthermore, induction of aneurysm in normocholesterolemic C57BL/6J mice resulted in a low incidence rate of AAA, supporting the requirement of high cholesterol levels for aneurysmal development (15,28).

Despite the lack of an overall effect on AAA formation, PCL pretreatment resulted in significantly decreased degradation of elastin. Elastin degradation has been suggested to be a key event in AAA formation (1,4). In addition, on the molecular level, the expression of one key gene for AAA development, Flna, was decreased in AngII-infused mice, and this was not observed in mice with PCL pretreatment. This indicated that the degree of vSMC phenotypic modulation and loss of vSMCs (29) in mice with PCL prior to infusion of AngII was less pronounced, further strengthening the hypothesis that plasma cholesterol levels are involved in aneurysmal formation.

Historically, AAA has been considered to be an outcome of atherosclerosis. However, data obtained from several previous studies investigating human and mouse AAA models has suggested that, in the majority of cases, atherosclerosis merely co-exists with AAA pathology (1,4). Taken together, the data obtained in the present study, where AngII-infusion was performed in Ldlr<sup>-/-</sup> Apob<sup>100/100</sup> Mttp<sup>flox/flox</sup> Mx1-Cre mice suggested that atherosclerosis and AAA are two separate diseases, which is consistent with data from other previous studies (1,4). The present study suggested that atherosclerosis and aneurysmal formation develop independently, but common factors, including plasma cholesterol levels, affect the two diseases. In addition, although it exerted a weak response on AAA formation, PCL treatment appeared to be of benefit. The fact that the mouse model used in the present study, which exhibited a modest increase in plasma cholesterol levels, had a low AAA occurrence rate. This indicated that plasma cholesterol levels are important for disease development. To fully address this issue, further studies in severe hypercholesterolemic mice are required.

**Acknowledgements**

Not applicable.

**Funding**

No funding was received.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.
Authors' contributions

AR contributed to the generation of the scientific hypothesis, study design, all animal experiments, immunohistochemistry (IHC) studies regarding the superior part of the aortas (arch and root) for cryosectioning and staining, as well as for en face pinning and atherosclerosis analysis. She performed further paraffin-IHC of the suprarenal aortas and the gene expression analysis, as well as all plasma measurements. She analysed all results and contributed to the manuscript composition. EV participated in the study design, performed part of the IHC studies regarding the suprarenal aortas in paraffin, contributed to the manuscript composition, gave feedback and revised it. AW participated in the study design, results' discussion and manuscript feedback and revision. TL participated in the discussion of the hypothesis, study design, data revision and interpretation. JS, EF and DW contributed to generate the discussion of the hypothesis, study design, data revision and manuscript feedback and revision. TL participated in the study design, performed part of the IHC analysis, as well as all plasma measurements. She analysed all results and contributed to the manuscript composition and revision.

Ethics approval and consent to participate

The protocol for the present study was approved by the Stockholm North Ethical Committee on Animal Research (ethical permit no. N223/14).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References